Інвазивний рак молочної залози
Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.
| ID | DIS-BREAST |
|---|---|
| Тип | Хвороба |
| Синоніми | BCInvasive breast cancerMammary carcinomaІнвазивний рак молочної залозиРМЗ |
| Статус | очікує клінічного підпису |
| Хвороби | Не вказано |
| Джерела | SRC-ESMO-BREAST-EARLY-2024 SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Інформаційна підтримка. Усі рекомендації має перевірити кваліфікований онколог. Технічні перевірки не є клінічною валідацією чи схваленням лікування.
| icd_o_3_morphology | 8500/3 |
|---|---|
| icd_o_3_topography | ["C50.9"] |
| icd_10 | C50 |
| who_classification | Invasive carcinoma of the breast (WHO 5th) |
Нотатки
Єдина нозологічна одиниця з біомаркер-керованим архетипом: рецепторний підтип (ER/PR/HER2) і статус BRCA/HRR є домінантними точками розгалуження алгоритму. Підстрати (рання та метастатична стадії) передано через поле applicable_to.stage_requirements у Indication. Рішення зберегти ОДНУ нозологічну одиницю (а не три) обґрунтоване таким: (1) спільні діагностичне обстеження, тестування біомаркерів та хірургічна парадигма; (2) спільні аспекти підтримуючої терапії — здоров'я кісткової тканини, збереження фертильності, психосоціальна підтримка; (3) розгалуження лікування повністю вирішується на рівні біомаркерних знахідок та Algorithm decision_tree, тому окремі нозологічні одиниці не потрібні. Рак молочної залози у чоловіків ведеться за тим самим алгоритмом з гендер-специфічними примітками щодо підтримуючої терапії та переносимості лікування.
Де використовується
Algorithms
ALGO-BCSC-BREAST- ALGO-BCSC-BREASTALGO-BOADICEA-V6-BREAST-OVARIAN- ALGO-BOADICEA-V6-BREAST-OVARIANALGO-BRCAPRO- ALGO-BRCAPROALGO-BREAST-1L- ALGO-BREAST-1LALGO-BREAST-HER2-POS-2L- ALGO-BREAST-HER2-POS-2LALGO-BREAST-HR-POS-2L- ALGO-BREAST-HR-POS-2LALGO-BREAST-TNBC-2L- ALGO-BREAST-TNBC-2LALGO-CASCADE-LFS-CARRIER-FAMILY-TESTING- ALGO-CASCADE-LFS-CARRIER-FAMILY-TESTINGALGO-CHOMPRET-2015-LFS- ALGO-CHOMPRET-2015-LFSALGO-COWDEN-CARRIER-SURVEILLANCE- ALGO-COWDEN-CARRIER-SURVEILLANCEALGO-GAIL-BREAST- ALGO-GAIL-BREASTALGO-MANCHESTER-BRCA- ALGO-MANCHESTER-BRCAALGO-PEUTZ-JEGHERS-CARRIER-SURVEILLANCE- ALGO-PEUTZ-JEGHERS-CARRIER-SURVEILLANCEALGO-TYRER-CUZICK-V8-BREAST- ALGO-TYRER-CUZICK-V8-BREAST
Drug Indications
DIND-ALPELISIB-BREAST-HR-POS-2L-PIK3CA- DIND-ALPELISIB-BREAST-HR-POS-2L-PIK3CA
Handbook Chapters
HB-BREAST-HER2-POS-MET-1L- HER2+ metastatic breast cancer: first-line reasoningHB-BREAST-HR-POS-HER2-NEG-1L- HR+/HER2- metastatic breast cancer: first-line reasoning
Procedures
PROC-GENETIC-COUNSELING-PRE-TEST- Pre-test genetic counseling encounter for germline cancer-susceptibility testingPROC-MAMMOGRAPHY-DIAGNOSTIC- Diagnostic mammography for evaluation of breast findingPROC-PROPHYLACTIC-BSO-BRCA- Risk-reducing bilateral salpingo-oophorectomy in BRCA1/2 carriersPROC-PROPHYLACTIC-MASTECTOMY-BRCA- Risk-reducing bilateral mastectomy for BRCA1/2 carriers
Questionnaires
QUEST-BREAST-1L-STUB- Invasive breast cancer — first line
Sources
SRC-APHINITY-VONMINCKWITZ-2017- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast CancerSRC-ASCENT-BARDIA-2021- Sacituzumab Govitecan in Metastatic Triple-Negative Breast CancerSRC-BERRY-BRCAPRO-1997- Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family hi...SRC-BOGDANOVA-NBN-2008- Nijmegen Breakage Syndrome mutations and risk of breast cancerSRC-BOLERO2-BASELGA-2012- Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast CancerSRC-CAPITELLO291-TURNER-2023- Capivasertib in Hormone Receptor-Positive Advanced Breast CancerSRC-CLEARY-BLM-2003- Heterozygosity for the BLM(Ash) mutation and cancer riskSRC-CLEOPATRA-SWAIN-2015- Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer (CLEOPAT...SRC-DESTINY-BREAST03-CORTES-2022- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast CancerSRC-DESTINY-BREAST04-MODI-2022- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerSRC-EMBRACA-LITTON-2018- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationSRC-EMERALD-BIDARD-2022- Elacestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy...SRC-EMILIA-VERMA-2012- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerSRC-ESMO-BREAST-EARLY-2024- ESMO Clinical Practice Guideline on Early Breast CancerSRC-ESMO-BREAST-METASTATIC-2024- ESMO Clinical Practice Guideline on Metastatic Breast CancerSRC-EVANS-MANCHESTER-BRCA-2017- The Manchester scoring system for predicting BRCA1 / BRCA2 mutation likelihood — refined...SRC-GAIL-1989- Projecting individualized probabilities of developing breast cancer for white females who...SRC-HER2CLIMB-MURTHY-2019- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerSRC-INAVO120-TURNER-2024- Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast CancerSRC-KATHERINE-VONMINCKWITZ-2019- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerSRC-KEYNOTE-355-CORTES-2020- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated...SRC-KEYNOTE-522-SCHMID-2022- Event-free Survival with Pembrolizumab in Early Triple-Negative Breast CancerSRC-LEE-BOADICEA-V6-2019- BOADICEA — a comprehensive breast cancer risk-prediction model incorporating genetic and...SRC-MAP3-EXEMESTANE-CHEMOPREVENTION-2011- Exemestane for breast-cancer prevention in postmenopausal women (NCIC CTG MAP.3 / ExCel)SRC-MONALEESA-2-HORTOBAGYI-2016- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerSRC-MONALEESA-3-SLAMON-2018- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Hu...SRC-MONALEESA-7-TRIPATHY-2018- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive,...SRC-MONARCH-2-SLEDGE-2017- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced B...SRC-MONARCH-3-GOETZ-2017- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast CancerSRC-MONARCHE-JOHNSTON-2023- Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-pos...SRC-NATALEE-SLAMON-2024- Ribociclib plus Endocrine Therapy in Early Breast CancerSRC-NCCN-BREAST-2025- NCCN Clinical Practice Guidelines — Breast CancerSRC-NSABP-P-1-TAMOXIFEN-1998- Tamoxifen for prevention of breast cancer — report of the National Surgical Adjuvant Brea...SRC-OLYMPIA-TUTT-2021- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast CancerSRC-OLYMPIAD-ROBSON-2017- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationSRC-PALOMA-2-FINN-2016- Palbociclib and Letrozole in Advanced Breast Cancer (PALOMA-2)SRC-PALOMA-3-TURNER-2015- Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer (PALOMA-3)SRC-SOLAR1-ANDRE-2019- Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast CancerSRC-STAR-TAMOXIFEN-RALOXIFENE-2006- Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and o...SRC-TICE-BCSC-2008- Using clinical factors and mammographic breast density to estimate breast cancer risk — d...- ... 2 ще
Клінічна застосовність
BMA-ATM-GERMLINE-BREAST- ATM germline pathogenic confers ~2× lifetime breast-cancer risk; no PARPi indication (TBC...BMA-ATM-SOMATIC-BREAST- Somatic ATM loss-of-function in breast: minimal PARPi activity in ATM-only basket arms; t...BMA-BARD1-GERMLINE-BREAST- BARD1 germline pathogenic confers moderate breast-cancer risk (~2-3×). BARD1 forms hetero...BMA-BARD1-SOMATIC-BREAST- Somatic BARD1 in breast: rare; biological HRR rationale only. ESCAT IIIA / OncoKB Level 3...BMA-BRCA1-GERMLINE-BREAST- BRCA1 germline pathogenic in HER2-negative metastatic breast (HR+ or TNBC): olaparib (Oly...BMA-BRCA1-SOMATIC-BREAST- Somatic BRCA1 loss-of-function in HER2-negative metastatic breast: TBCRC-048 (Tung 2020)...BMA-BRCA2-GERMLINE-BREAST- BRCA2 germline pathogenic in HER2-negative metastatic breast: olaparib (OlympiAD) and tal...BMA-BRCA2-SOMATIC-BREAST- Somatic BRCA2 loss-of-function in HER2-neg metastatic breast: TBCRC-048 demonstrated tala...BMA-BRIP1-GERMLINE-BREAST- BRIP1 germline pathogenic and breast cancer: weak/uncertain risk association (NCCN does n...BMA-BRIP1-SOMATIC-BREAST- Somatic BRIP1 in breast: rare; no actionable indication. ESCAT IV / OncoKB Level 4.BMA-CHEK2-GERMLINE-BREAST- CHEK2 germline pathogenic (e.g. 1100delC) confers ~2× breast-cancer risk; no PARPi activi...BMA-CHEK2-SOMATIC-BREAST- Somatic CHEK2 in breast: minimal PARPi activity; standard subtype-directed therapy. ESCAT...BMA-CTDNA-MRD-POST-TREATMENT-BREAST- Personalized tumor-informed ctDNA assays detect MRD before clinical/ radiographic recurre...BMA-ESR1-MUT-BREAST- ESR1 ligand-binding-domain mutations confer aromatase-inhibitor (AI) resistance through c...BMA-FGFR1-AMP-BREAST- FGFR1 amplification in HR+ breast cancer (~10-15%): prognostic for endocrine-therapy resi...BMA-HER2-LOW-BREAST- Trastuzumab deruxtecan (T-DXd, DS-8201) is FDA-approved (Aug 2022) for unresectable or me...BMA-HRD-STATUS-BREAST- Germline BRCA1/2 mutation (gBRCAm) breast cancer (HER2-negative, ~5-10% of metastatic): o...BMA-PALB2-GERMLINE-BREAST- PALB2 germline pathogenic confers BRCA-like breast risk (~50% lifetime). Olaparib activit...BMA-PALB2-SOMATIC-BREAST- Somatic PALB2 loss-of-function in breast: small TBCRC-048 cohort included sPALB2 with PAR...BMA-PIK3CA-E542K-BREAST- PIK3CA hotspot mutations (~40% of HR+/HER2- metastatic breast cancer): alpelisib + fulves...BMA-PIK3CA-E545K-BREAST- PIK3CA hotspot mutations (~40% of HR+/HER2- metastatic breast cancer): alpelisib + fulves...BMA-PIK3CA-EXON20-BREAST- PIK3CA hotspot mutations (~40% of HR+/HER2- metastatic breast cancer): alpelisib + fulves...BMA-PIK3CA-EXON9-BREAST- PIK3CA hotspot mutations (~40% of HR+/HER2- metastatic breast cancer): alpelisib + fulves...BMA-PIK3CA-H1047L-BREAST- PIK3CA hotspot mutations (~40% of HR+/HER2- metastatic breast cancer): alpelisib + fulves...BMA-PIK3CA-H1047R-BREAST- PIK3CA hotspot mutations (~40% of HR+/HER2- metastatic breast cancer): alpelisib + fulves...BMA-RAD51B-GERMLINE-BREAST- RAD51B germline pathogenic in breast: moderate-risk allele (~RR 2-4 for RAD51C/D, less es...BMA-RAD51B-SOMATIC-BREAST- Somatic RAD51B in breast: rare; HRR-rationale only. ESCAT IIIA / OncoKB Level 4.BMA-RAD51C-GERMLINE-BREAST- RAD51C germline pathogenic in breast: moderate-risk allele (~RR 2-4 for RAD51C/D, less es...BMA-RAD51C-SOMATIC-BREAST- Somatic RAD51C in breast: rare; HRR-rationale only. ESCAT IIIA / OncoKB Level 4.BMA-RAD51D-GERMLINE-BREAST- RAD51D germline pathogenic in breast: moderate-risk allele (~RR 2-4 for RAD51C/D, less es...BMA-RAD51D-SOMATIC-BREAST- Somatic RAD51D in breast: rare; HRR-rationale only. ESCAT IIIA / OncoKB Level 4.BMA-RAD54L-GERMLINE-BREAST- RAD54L germline variants: rare; HR-pathway gene with limited clinical evidence. Included...BMA-RAD54L-SOMATIC-BREAST- Somatic RAD54L: very rare; biological HRR rationale only. ESCAT IV / OncoKB Level 4.BMA-TP53-MUT-BREAST- TP53 mutations in breast — common in TNBC and basal-like; adverse prognostic. Not directl...BMA-TP53-R175H-BREAST- TP53 hotspot in TNBC / luminal — adverse prognostic; not directly targeted. Hotspot R175H...BMA-TP53-R248Q-BREAST- TP53 hotspot in TNBC / luminal — adverse prognostic; not directly targeted. Hotspot R248Q...BMA-TP53-R273H-BREAST- TP53 hotspot in TNBC / luminal — adverse prognostic; not directly targeted. Hotspot R273H...BMA-TP53-R282W-BREAST- TP53 hotspot in TNBC / luminal — adverse prognostic; not directly targeted. Hotspot R282W...
Показання
IND-ATM-CARRIER-PREVENTION-OBSERVATION- IND-ATM-CARRIER-PREVENTION-OBSERVATIONIND-ATM-CARRIER-PREVENTION-SURVEILLANCE- IND-ATM-CARRIER-PREVENTION-SURVEILLANCEIND-ATM-SUSPICION-PREVENTION-EMPIRICAL-SURVEILLANCE- IND-ATM-SUSPICION-PREVENTION-EMPIRICAL-SURVEILLANCEIND-ATM-SUSPICION-PREVENTION-TESTING- IND-ATM-SUSPICION-PREVENTION-TESTINGIND-BARD1-CARRIER-PREVENTION-OBSERVATION- IND-BARD1-CARRIER-PREVENTION-OBSERVATIONIND-BARD1-CARRIER-PREVENTION-SURVEILLANCE- IND-BARD1-CARRIER-PREVENTION-SURVEILLANCEIND-BARD1-SUSPICION-PREVENTION-EMPIRICAL-SURVEILLANCE- IND-BARD1-SUSPICION-PREVENTION-EMPIRICAL-SURVEILLANCEIND-BARD1-SUSPICION-PREVENTION-TESTING- IND-BARD1-SUSPICION-PREVENTION-TESTINGIND-BRCA-CARRIER-INTENSIFIED- IND-BRCA-CARRIER-INTENSIFIEDIND-BRCA-CARRIER-SURVEILLANCE- IND-BRCA-CARRIER-SURVEILLANCEIND-BRCA-HBOC-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE- IND-BRCA-HBOC-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCEIND-BRCA-HBOC-SUSPICION-PREVENTION-GENETIC-COUNSELING- IND-BRCA-HBOC-SUSPICION-PREVENTION-GENETIC-COUNSELINGIND-BREAST-BRCA-MET-TALAZOPARIB- IND-BREAST-BRCA-MET-TALAZOPARIBIND-BREAST-BRCA-POS-MET-PARPI- IND-BREAST-BRCA-POS-MET-PARPIIND-BREAST-HER2-LOW-2L-DATO-DXD- IND-BREAST-HER2-LOW-2L-DATO-DXDIND-BREAST-HER2-POS-3L-TUCATINIB- IND-BREAST-HER2-POS-3L-TUCATINIBIND-BREAST-HER2-POS-EARLY-NEOADJUVANT- IND-BREAST-HER2-POS-EARLY-NEOADJUVANTIND-BREAST-HER2-POS-MAINT-TRAST- IND-BREAST-HER2-POS-MAINT-TRASTIND-BREAST-HER2-POS-MET-1L-THP- IND-BREAST-HER2-POS-MET-1L-THPIND-BREAST-HER2-POS-MET-2L-TDXD- IND-BREAST-HER2-POS-MET-2L-TDXDIND-BREAST-HR-POS-1L-INAVOLISIB- IND-BREAST-HR-POS-1L-INAVOLISIBIND-BREAST-HR-POS-2L-AKT-CAPIVASERTIB- IND-BREAST-HR-POS-2L-AKT-CAPIVASERTIBIND-BREAST-HR-POS-2L-DATO-DXD- IND-BREAST-HR-POS-2L-DATO-DXDIND-BREAST-HR-POS-2L-ESR1-ELACESTRANT- IND-BREAST-HR-POS-2L-ESR1-ELACESTRANTIND-BREAST-HR-POS-2L-FUL-EVEROLIMUS- IND-BREAST-HR-POS-2L-FUL-EVEROLIMUSIND-BREAST-HR-POS-2L-PIK3CA-ALPELISIB- IND-BREAST-HR-POS-2L-PIK3CA-ALPELISIBIND-BREAST-HR-POS-2L-T-DXD-HER2-LOW- IND-BREAST-HR-POS-2L-T-DXD-HER2-LOWIND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKT- IND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKTIND-BREAST-HR-POS-EARLY-ADJ-CDK46I- IND-BREAST-HR-POS-EARLY-ADJ-CDK46IIND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB- IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIBIND-BREAST-HR-POS-MAINT-CDK46I- IND-BREAST-HR-POS-MAINT-CDK46IIND-BREAST-HR-POS-MET-1L-CDKI- IND-BREAST-HR-POS-MET-1L-CDKIIND-BREAST-TNBC-2L-BRCA-OLAPARIB- IND-BREAST-TNBC-2L-BRCA-OLAPARIBIND-BREAST-TNBC-2L-BRCA-TALAZOPARIB- IND-BREAST-TNBC-2L-BRCA-TALAZOPARIBIND-BREAST-TNBC-2L-DATO-DXD- IND-BREAST-TNBC-2L-DATO-DXDIND-BREAST-TNBC-2L-SACITUZUMAB- IND-BREAST-TNBC-2L-SACITUZUMABIND-BREAST-TNBC-2L-T-DXD-HER2-LOW- IND-BREAST-TNBC-2L-T-DXD-HER2-LOWIND-BREAST-TNBC-3L-POST-SACI-POST-T-DXD- IND-BREAST-TNBC-3L-POST-SACI-POST-T-DXDIND-BREAST-TNBC-EARLY-NEOADJUVANT- IND-BREAST-TNBC-EARLY-NEOADJUVANTIND-BREAST-TNBC-METASTATIC-1L-PEMBRO-CHEMO- IND-BREAST-TNBC-METASTATIC-1L-PEMBRO-CHEMO- ... 44 ще
Схема лікування
REG-PEMBRO-CHEMO-TNBC-MET- Pembrolizumab + chemotherapy (TNBC, metastatic PD-L1+)
Тривожна ознака
RF-ACTIVE-AUTOIMMUNE-DISEASE-ICI-RISK- Patient with active or incompletely controlled pre-existing autoimmune or inflammatory di...RF-ATM-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic monoallelic variant in ATM (heterozygou...RF-ATM-FAMILY-HISTORY-SUSPICION- Family pedigree pattern suggestive of germline ATM heterozygous carrier state in an asymp...RF-BARD1-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in BARD1 (BRCA1-associated RING...RF-BARD1-FAMILY-HISTORY-SUSPICION- Family pedigree pattern suggestive of germline BARD1 heterozygous carrier state in an asy...RF-BLM-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in the BLM gene — Bloom syndrom...RF-BRCA-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in BRCA1 or BRCA2 — the canonic...RF-BRCA-HBOC-FAMILY-HISTORY-SUSPICION- Family pedigree meeting criteria suggestive of Hereditary Breast and Ovarian Cancer (HBOC...RF-BREAST-AKT1-E17K-ACTIONABLE- AKT1 E17K activating mutation in HR+/HER2- metastatic breast cancer — ~3-6% prevalence. C...RF-BREAST-AKT1-E17K-CAPIVASERTIB-CANDIDATE- AKT1 E17K activating hotspot specifically positioning capivasertib + fulvestrant in HR+/H...RF-BREAST-BRCA-GERMLINE-ACTIONABLE- Germline BRCA1 or BRCA2 pathogenic variant in HER2-negative breast cancer (HR+ or TNBC)....RF-BREAST-CDH1-LOBULAR-CANDIDATE- Germline CDH1 (E-cadherin) pathogenic variant in invasive lobular breast carcinoma — INFO...RF-BREAST-EARLY-STAGE- Early-stage (non-metastatic) breast cancer: clinical or pathological stage I, II, or III....RF-BREAST-ESR1-MUT-ACTIONABLE- ESR1 ligand-binding-domain mutation (D538G, Y537S/N/C, L536H, E380Q) acquired in ~30-40%...RF-BREAST-ESR1-Y537S-D538G-CANDIDATE- ESR1 ligand-binding-domain hotspot Y537S or D538G — the two dominant hotspots (~70% of al...RF-BREAST-FRAILTY-AGE- Age ≥75 + ECOG ≥2 + significant comorbidity — anthracycline + dose-dense regimens poorly...RF-BREAST-HER2-AMP-ACTIONABLE- HER2 amplification / overexpression in breast cancer (IHC 3+ OR IHC 2+ with ISH amplified...RF-BREAST-HER2-LOW-ACTIONABLE- HER2-low breast cancer (IHC 1+ OR IHC 2+ with non-amplified ISH) — ~50-55% of HER2-non-po...RF-BREAST-HER2-ULTRALOW-CANDIDATE- HER2-ultralow breast cancer (IHC > 0 < 1+; faint/incomplete membrane staining ≤10% of tum...RF-BREAST-HIGH-RISK-BIOLOGY- Germline or somatic BRCA1/2 mutation, PIK3CA mutation, ESR1 mutation, HER2-amplification,...RF-BREAST-INFECTION-SCREENING- HBV/HCV/HIV serology + dental evaluation pre-bisphosphonate/denosumab + DPYD genotyping f...RF-BREAST-ORGAN-DYSFUNCTION- Cardiac dysfunction (LVEF <50%) — anthracycline + trastuzumab/pertuzumab + T-DM1/T-DXd al...RF-BREAST-OVARIAN-HRD-ASSAY-DISTINCTION- HRD assay platform mismatch in breast or ovarian cancer: HRD-positive call by Myriad myCh...RF-BREAST-PIK3CA-COALT-INAVOLISIB-CANDIDATE- PIK3CA-mutant HR+/HER2- metastatic breast with co-alteration profile (endocrine-resistant...RF-BREAST-PIK3CA-MUT-ACTIONABLE- PIK3CA hotspot activating mutation (E542K, E545K, H1047R/L) in HR+/HER2- metastatic breas...RF-BREAST-STAGE-IV-METASTATIC- Metastatic (stage IV) breast cancer: presence of distant metastasis (M1 per TNM 8th editi...RF-BREAST-TNBC- Triple-negative breast cancer (TNBC): estrogen receptor (ER) <1% nuclear staining on IHC...RF-BREAST-TRANSFORMATION-PROGRESSION- Symptomatic CNS metastases OR rapid visceral progression on current therapy — emergency-t...RF-CASCADE-BRCA-FDR-POSITIVE- A first-degree relative of the patient (parent, sibling, or child) has a documented posit...RF-CASCADE-LFS-FDR-POSITIVE- A first-degree relative of the patient (parent, sibling, or child) has a documented posit...RF-CHEK2-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic monoallelic variant in CHEK2. Most comm...RF-CHEK2-FAMILY-HISTORY-SUSPICION- Family pedigree pattern suggestive of germline CHEK2 heterozygous carrier state in an asy...RF-CHRONIC-SEVERE-OBESITY-BMI40-PREVENTION- Severe obesity — BMI ≥40 kg/m² (WHO class III obesity), distinct from the broader RF-LIFE...RF-CHRONIC-T2DM-CANCER-RISK-PREVENTION- Established type-2 diabetes mellitus (HbA1c ≥6.5% on two occasions, or established T2DM d...RF-COWDEN-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in the PTEN gene (Cowden syndro...RF-COWDEN-FAMILY-HISTORY-SUSPICION- Family pedigree suggestive of Cowden syndrome / PTEN hamartoma tumor syndrome (PHTS): any...RF-HDGC-CDH1-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in CDH1 (E-cadherin) — Heredita...RF-IATROGENIC-COMBINED-HRT-PREVENTION- Cumulative use of combined hormone replacement therapy (estrogen + progestin / progestoge...RF-IATROGENIC-IODINE131-SECONDARY-PREVENTION- Therapeutic radioiodine (I-131) exposure for differentiated thyroid cancer (DTC) ablation...RF-IATROGENIC-LONG-TERM-HRMNL-CONTRACEPTION-PREVENTION- Cumulative use of estrogen-containing or combined hormonal contraception (combined oral c...- ... 26 ще
Хвороба
DIS-CHOROID-PLEXUS-CARCINOMA- Choroid plexus carcinoma